Compare IDEXX Laboratories, Inc. (IDXX) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Weibo Corp — how do they compare? IDEXX Laboratories, Inc. trades at $552.03 (market cap $44.48B), while Weibo Corp trades at $8 (market cap $1.95B). The key difference: IDEXX Laboratories, Inc. is far larger — about 22.8× Weibo Corp's market cap, and Weibo Corp pays a 7.63% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | WB | |
|---|---|---|
Market Cap | $44.48B | $1.95B |
Sector | Health | Media |
52-Week High | $766.68 | $12.83 |
52-Week Low | $520.87 | $7.20 |
Enterprise Value | $45.38B | $1.22B |
Dividend Yield | — | 7.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
Weibo (WB) trades at $7.995, up 3.16% today, with a bullish technical signal from moving averages but overbought RSI readings. The stock shows deep value with a P/E of 5.42 and P/B of 0.49, supported by strong profitability including a 21.15% net margin. Recent earnings have slightly missed expectations, but revenue remains stable at $1.76 billion for 2025. News highlights Weibo's cash flow generation and inclusion in value stock lists, though competitive pressures are noted.
The outlook balances significant undervaluation against competitive and execution risks. The market cap of approximately $1.8 billion is below the net balance sheet value, suggesting a margin of safety. Key risks include user engagement challenges from rivals like Douyin and reliance on advertising revenue. Analyst sentiment is mixed but leans positive, with 45% recommending Buy. The stock presents a value opportunity contingent on successful business execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
